医学
化疗
阶段(地层学)
安慰剂
肿瘤科
肺癌
内科学
随机对照试验
癌症
病理
替代医学
古生物学
生物
作者
Ying Cheng,Ying Li,W. Zhang,Lin Wu,Caicun Zhou,D. Wang,Bai Xiu-juan,Minghong Bi,Xiaorui Fu,Chunde Li,G. Chen,Dongqing Lv,Yanqiu Zhao,Jianan Huang,Ming Li,Tienan Yi,Xiao‐Jun Huang,Runxiang Yang,Z. Chen,Yan Wang
标识
DOI:10.1016/j.annonc.2023.10.096
摘要
Combinations of immunotherapy with chemotherapy as a first-line treatment for ES-SCLC have generated mixed results. The EXTENTORCH trial assessed toripalimab in combination with chemotherapy as a first-line treatment for patients with ES-SCLC (NCT04012606).
科研通智能强力驱动
Strongly Powered by AbleSci AI